Gupta A, Chacko VP, Weiss RG. Abnormal energetics and ATP depletion in pressure-overload mouse hearts: in vivo high-energy phosphate concentration measures by noninvasive magnetic resonance. Am J Physiol Heart Circ Physiol 297: H59 -H64, 2009. First published May 15, 2009 doi:10.1152/ajpheart.00178.200931 P magnetic resonance spectroscopy (MRS) offers a unique means to noninvasively quantify the major cardiac high-energy phosphates, creatine phosphate (PCr) and adenosine 5Ј-triphosphate (ATP), that are critical for normal myocardial contractile function and viability. Spatially localized 31 P MRS has been used to quantify the in vivo PCr-to-ATP ratio (PCr/ATP) of murine hearts, including those with pressure-overload hypertrophy induced by thoracic aortic constriction (TAC). To date, there has been no approach for measuring the absolute tissue concentrations of PCr and ATP in the in vivo mouse heart that promise a better understanding of high-energy metabolism. A method to quantify in vivo murine myocardial concentrations of PCr and ATP using an external reference is described, validated, and applied to normal and TAC hearts. This new method does not prolong the scan times in mice beyond those previously required to measure PCr/ATP. The new method renders an [ATP] of 5.0 Ϯ 0.9 (mean Ϯ SD) and [PCr] of 10.4 Ϯ 1.4 mol/g wet wt in normal mouse hearts (n ϭ 7) and significantly lower values in TAC hearts (n ϭ 10) of 4.0 Ϯ 0.8 and 6.7 Ϯ 2.0 mol/g wet wt for [ATP] (P Ͻ 0.04) and [PCr] (P Ͻ 0.001), respectively. The in vivo magnetic resonance [ATP] results are in good agreement with those obtained using an in vitro enzyme luminescent assay of perchloric acid extracts of the same hearts. In conclusion, a validated 31 P MRS method for quantifying [ATP] and [PCr] in the in vivo mouse heart using spatial localization and an external reference is described and used to demonstrate significant reductions in not only PCr/ATP but [ATP] in hypertrophied TAC hearts. adenosine 5Ј-triphosphate; phosphocreatine; magnetic resonance spectroscopy; hypertrophy MOST BIOCHEMICAL STUDIES by magnetic resonance (MR) have exploited the phosphorus ( 31 P) MR signal because high-energy phosphate-containing compounds occupy a central role in the bioenergetics of living cells and are present in sufficiently high concentrations (Ͼ0.5 mM) to be detectable by MR spectroscopy (MRS). In addition, the sensitivity of the naturally abundant 31 P nucleus is relatively high (one-fifteenth that of 1 H), and the chemical shift range is fairly wide (about 30 parts per million for biological phosphates). Thus 31 P MRS has been used for several decades to obtain information on energy metabolism in a nondestructive manner. In the healthy and diseased heart, 31 P MRS has been exploited to noninvasively detect adenosine 5Ј-triphosphate (ATP), the primary biochemical source of energy and creatine phosphate (PCr), a highenergy storage and transport molecule (12, 18, (27) (28) . The relative amount of PCr and ATP, the PCr-to-ATP ratio (PCr/ ATP), is typically reported in experimental and clinical MRS studies because it is measured in a single MRS acquisition, provides important insights into energy metabolism in the healthy heart, and is perturbed by common pathological conditions (7, 9, 28). However, the myocardial PCr/ATP does not provide a complete picture of myocardial energy metabolism. An absolute quantification of these high-energy phosphate metabolites is technically more challenging than a measurement of PCr/ATP, but it alone can detect changes in the ATP pool size. In addition, the size of the PCr pool is used in the calculation of ATP flux through the creatine kinase (CK) reaction in magnetization transfer studies, and this flux is critically altered in experimental and human heart failure (HF) (26, 29, 31) . Thus an absolute quantification of [PCr] and [ATP] promises more profound bioenergetic insights than the conventional PCr/ATP alone.
adenosine 5Ј-triphosphate; phosphocreatine; magnetic resonance spectroscopy; hypertrophy MOST BIOCHEMICAL STUDIES by magnetic resonance (MR) have exploited the phosphorus ( 31 P) MR signal because high-energy phosphate-containing compounds occupy a central role in the bioenergetics of living cells and are present in sufficiently high concentrations (Ͼ0.5 mM) to be detectable by MR spectroscopy (MRS). In addition, the sensitivity of the naturally abundant 31 P nucleus is relatively high (one-fifteenth that of 1 H), and the chemical shift range is fairly wide (about 30 parts per million for biological phosphates). Thus 31 P MRS has been used for several decades to obtain information on energy metabolism in a nondestructive manner. In the healthy and diseased heart, 31 P MRS has been exploited to noninvasively detect adenosine 5Ј-triphosphate (ATP), the primary biochemical source of energy and creatine phosphate (PCr), a highenergy storage and transport molecule (12, 18, (27) (28) . The relative amount of PCr and ATP, the PCr-to-ATP ratio (PCr/ ATP), is typically reported in experimental and clinical MRS studies because it is measured in a single MRS acquisition, provides important insights into energy metabolism in the healthy heart, and is perturbed by common pathological conditions (7, 9, 28) . However, the myocardial PCr/ATP does not provide a complete picture of myocardial energy metabolism. An absolute quantification of these high-energy phosphate metabolites is technically more challenging than a measurement of PCr/ATP, but it alone can detect changes in the ATP pool size. In addition, the size of the PCr pool is used in the calculation of ATP flux through the creatine kinase (CK) reaction in magnetization transfer studies, and this flux is critically altered in experimental and human heart failure (HF) (26, 29, 31) . Thus an absolute quantification of [PCr] and [ATP] promises more profound bioenergetic insights than the conventional PCr/ATP alone.
Several approaches for measuring absolute concentrations of high-energy phosphate metabolites in the human heart have been reported, and virtually all rely on comparisons with signal from a 31 P standard reference as well as estimates of myocardial mass in the MRS volume of interest detected by concomitant MR imaging (MRI) or MRS (2-4, 15-16, 19 -20, 30) .
Mouse models offer a novel, appealing means to investigate the mechanistic links between altered energy metabolism and function that are currently not possible in larger mammalian species and humans because they allow gene-targeted interventions. In several important ways murine models mimic functional and energetic aspects of normal human cardiac physiology (6) . Thoracic aortic constriction (TAC) in the mouse results in pressure-overload hypertrophy that progresses and shares many energetic and functional aspects with clinical human HF (14) . Although PCr/ATP measures have been validated in the in vivo mouse heart (6, 14) , there have been no methods validated for measuring [ATP] or [PCr] . Thus there were two aims for this study. First, we sought to adapt human 31 
MATERIALS AND METHODS
MR protocol. The procedure and protocols were reviewed and approved by the Institutional Animal Care and Use Committee of the Johns Hopkins University. Briefly, experiments were carried out on a Bruker Biospec MRI/MRS spectrometer equipped with a 4.7-T/40-cm Oxford magnet and a 12-cm (inner diameter) actively shielded gradient set, as previously described (6, 14, 17) . Studies were first performed on mice and, then, on the same day, on an external phantom using comparable protocols. More specifically, in vivo MRI/MRS studies were carried out on 7 wild-type male control mice (weight, 44 Ϯ 6.5 g) and 10 others 4 wk after TAC (weight, 41 Ϯ 6.3 g). Anesthesia was induced by ϳ1% isoflurane, as previously described (6, 14, 17 16 -phase encoding steps; NEX ϭ 64; TR ϭ 2,000 ms; and receiver gain ϭ 8,000) using modified BIR4 90°adiabatic pulses. After the mouse exams were completed, an external phantom, consisting of a 5-mm NMR tube filled with 0.15 M phosphate solution, containing 1) a combination of 0.075 M NaH2PO4 and 0.075 M Na2HPO4 and 2) 40 M NiCl2, was positioned at the center of the 31 P surface coil, like the mouse hearts, and studied with the same MRI/ MRS protocol, except that NEX was 2 and TR was 8,000 ms (fully relaxed due to NiCl2).
1 H MR images were analyzed with commercial Paravision software, and 31 P MR spectra peak areas were determined with in-house custom software (1) . Metabolite areas were determined from the integrated peak areas of the PCr and [␤-P] ATP resonances from voxels centered on cardiac muscle as identified from the highresolution 1 H MR images ( Fig. 1) , as described previously (6, 17) . Voxel shifting was performed when necessary to optimize slice alignment with cardiac structures and to minimize skeletal muscle contamination of cardiac spectra (5). The same slice was selected to measure the inorganic phosphate peak area in the external phosphate phantom studied after the mice. After the MRI/MRS study was completed, the mice were euthanized and the hearts immediately frozen in liquid nitrogen and later weighed. Cardiac tissues were suspended in 1,000 l of 0.4 M perchloric acid and homogenized. The suspension was then centrifuged for 5 min at 3,000 g at 4°C. The perchlorate anion was precipitated by the addition of 250 l of 1.0 M K 2HPO4 to the supernatant and then removed by centrifugation for 5 min at 3,000 g at 4°C. The supernatant was used for in vitro measurement of [PCr] and [ATP] with a luciferase enzyme LA method (23) . The LA assay consisted of pipetting cardiac tissue extracts and reagent assay solutions (23), in duplicate, into a Lumitrac flat-bottom white plate (Fisher Scientific, Pittsburgh, PA). The output light was measured using a Victor 3, 1420 multilabel counter luminometer (PerkinElmer, Fremont, CA) and compared with that from standard solutions.
Concentration calculations. The concentration of metabolite [C c], in one slice of a 31 P one-dimensional chemical shift imaging cardiac data set is given by the following equation:
where Sp and Sc are the signal intensities of phantom and cardiac metabolites, respectively; Cp and Cc are the concentration of the phantom and cardiac metabolites; Vp and Vc are the volumes of phantom and cardiac muscle in a slice equidistant from the center of the 31 P coil; NEXp and NEXc are the number of acquisitions for phantom and cardiac studies; and Cf is the saturation correction factor. To measure the T1-dependent correction factors (Cf) for PCr and ATP separately, we compared acquisitions under fully relaxed conditions with those of different TRs of 2, 4, 8, 10, 12 s from unlocalized mouse surface coil spectra. The values determined for C f were 0.6 and 0.9 for PCr and ATP from the TR of 12-s acquisitions. The [PCr] and [ATP] of normal and TAC mice were compared using Student's t-test and one-way ANOVA. Differences were considered statistically significant at P Յ 0.05. All results are shown as means Ϯ SD.
RESULTS
Representative high-resolution transverse 1 H MR images and spatially localized 31 P MR spectra are shown in Fig. 1 . The results of the 31 P MRS and LA methods are summarized in Fig. 2 . We observe a mean in vivo myocardial PCr/ATP of 2.1 Ϯ 0.3 for control mice, which is consistent with prior reports (6, 14, 17) . In control mice, the mean in vivo [PCr] and [ATP] by 31 P MRS of 10 Ϯ 1.4 and 5.0 Ϯ 0.9 mol/g wet wt, respectively, agree with prior in vitro measures (10, 22, 24 [PCr] is significantly higher by MRS (P Ͻ 0.003) when compared with LA, and this is likely due to the well-recognized rapid degradation of PCr during euthanasia (8, 11, 13) . Table 1 (Fig. 2) . Again, there is no significant difference in [ATP] determined by 31 P MRS and that by LA (P ϭ NS). Importantly, [PCr] is significantly decreased in TAC mice compared with controls by both MRS (P Ͻ 0.001) as well as LA (P Ͻ 0.0003), whereas [ATP] is also significantly decreased in TAC mice by MRS (P Ͻ 0.04) as well as LA (P Ͻ 0.02).
DISCUSSION
The first approach to quantify [ATP] and [PCr] in the in vivo mouse heart is presented. It uses noninvasive, spatially localized 31 P MRS and an external reference; it does not prolong the in vivo 31 P MRS exam over prior approaches to measure PCr/ATP alone, and the results agree with those previously reported in isolated hearts (Table 1) and with current in vivo findings using conventional biochemical measures (Fig. 2) . The new approach detects significant reductions of ϳ20% in mean [ATP] and 34% in mean [PCr] in hypertrophied TAC hearts. This practical, validated method to measure myocardial high-energy phosphate concentrations under physiological conditions offers a new window to in vivo cardiac bioenergetics and its role in common pathological conditions in mouse models of human disease.
PCr and ATP are the primary cardiac high-energy phosphates, and they can be quantified in vivo with 31 P MRS down to the practical limits (a few mM) of anatomic and functional resolution, which are related. Normal energy metabolism is critical for cardiac function and viability (12, 18) . The combination of 31 P MRS and MRI is uniquely able to assess the critical relationship between metabolism and function in the in vivo beating heart. Although the concentration of highenergy phosphate metabolites can be measured by enzymatic methods on processed cardiac tissue (21), 31 P MRS is the only noninvasive technique for measuring high-energy phosphates under in vivo conditions. The clinical relevance of the in vivo relationship between metabolism and function in the beating heart is evidenced by 31 P MRS/MRI studies in HF patients documenting reductions in the PCr/ATP, the concentrations of [ATP] and [PCr] , and in ATP flux through the CK reaction (12, 18, 26, 29) . Each of these metabolic parameters has different biological significance that has been previously reviewed in detail (12, 18) . Briefly, PCr/ATP is the simplest of the three bioenergetic parameters to measure with acute, transient, stressinduced reductions, suggesting ischemia (28) and chronic, longerterm changes reflecting alterations in the creatine pool (12, 25) .
[ATP] and [PCr] are the time-averaged absolute concentrations of the major high-energy phosphate pools, whereas the rate of ATP production via the CK reaction represents that amount of ATP generated per unit time via the main myocardial energy reserve. The last is the most challenging parameter to measure but promises valuable bioenergetic insight as the high-energy phosphate pools are relatively small relative to their high rate of turnover (24, 26, 29) .
The mouse is a commonly used, important model for many human diseases because it allows specific gene-targeted interventions of overexpression or knockout. In the absence of genetic manipulation, the normal mouse heart exhibits some fundamental similarities to the normal human heart in highenergy phosphate metabolism and global left ventricular ejection fraction (6, 17) . Our results demonstrate that it is convenient to perform studies of murine cardiac high-energy phosphate metabolism under in vivo conditions with the use of these image-guided, spatially localized 31 P MRS techniques, despite the small body (30 -45 g) and heart weights (80 -120 mg) as well as the rapid heart rates (450 -600 beats/min).
With this quantitative, noninvasive 31 P MRS approach in the in vivo mouse heart, [ATP] measurements were similar to those obtained in vitro by the highly sensitive LA method (P ϭ NS). However, in vivo MRS measurements of [PCr] were significantly higher (P Ͻ 0.003) than those obtained with the in vitro LA method performed on heart extracts. This difference is attributable to the well-known rapid degradation of PCr during euthanasia (8, 11, 13) . It is also reassuring that our in vivo and in vitro measurements of [ATP] and [PCr] are consistent with the prior reported literature values ( Table 1 ). The prior in vitro mean mouse measures of ϳ8.9 and 4.3 mol/g wet wt for [PCr] and [ATP], respectively (Table 1) , are similar to our in vitro measures and only slightly lower than the range previously reported from normal human hearts (Table 1 ). Technical differences in MR localization and quantification techniques likely account for the differences observed among human studies (Table 1) , whereas the slightly lower values often observed in in vitro studies as compared with more physiological in vivo studies may be related, in part, to some loss of high-energy phosphates during euthanasia-associated ischemia (8, 11, 13) or sample preparation. As the new approach only requires the acquisition of data from a 31 Pcontaining phantom under conditions similar to that of a mouse study, it does not increase the time of an anesthetized mouse study. While normal mice easily tolerate isoflurane anesthesia, significantly extending an in vivo MRS/MRI exam could prove problematic for severely ill mice that do not always tolerate prolonged anesthesia, including those with significant left ventricular dysfunction following TAC.
A novel finding here is that [ATP] is reduced after TAC in the in vivo mouse heart. Prior studies have shown lower cardiac PCr/ATP in pressure-overload conditions in larger animals (31) and in the TAC mouse heart (14) . In addition, reduced PCr/ATP preceded systolic dysfunction in the TAC mouse heart and predicted subsequent ventricular remodeling (14) . The new observation that [ATP] decreases in TAC hearts means that the normal well-integrated metabolic machinery of the normal heart has failed and that the mechanisms which slowly replete ATP pools are inadequate. The decrease in [ATP] is significant because it signals a significant change in normal metabolic regulation, one that is unable to support normal levels of either ATP or PCr (12) . Comparable decreases in [ATP] have also been reported in large animal models of HF including pressure overload (32) and pacing tachycardia (25) .
The ability to quantify the concentrations of high-energy phosphates in murine HF models may eventually provide important insights beyond the ability to detect a decline in the 24 ). The forward rate of ATP synthesis through the CK reaction is significantly reduced in human HF (26, 29) and is calculated by the product of [PCr] and the pseudo-first-order CK rate constant, the latter determined by magnetization transfer methods. Thus this first method to measure [ATP] and [PCr] in the in vivo beating mouse heart offers new biological insights for future work into understanding the potential metabolic consequences and cause of HF in mouse models.
There are several limitations to the current work. First, because of the low sensitivity of 31 P MRS, this in vivo method cannot quantify extremely low metabolic concentrations (Ͻ0.5 mM) or study minutely small volumes such as that of a single fiber. Nevertheless, it can be used to interrogate the anterior wall of the in vivo beating mouse heart and detect significant changes in [ATP] and [PCr] in a relevant HF model. Second, although the approach renders tissue rather than intracellular high-energy phosphate concentrations, tissue concentrations are the ones obtained in human MRS/MRI studies and used, in part, to calculate ATP flux through the CK reaction. Moreover tissue concentrations are commonly converted to intracellular concentrations by correcting for the intracellular space (10, 22, 24) .
In summary, the first noninvasive means to quantify [ATP] and [PCr] in the in vivo beating mouse heart is reported, validated, and used to identify significant reductions in [ATP] in the TAC model of HF. This quantitative advance promises new bioenergetic insights over the more conventional cardiac PCr/ATP alone and thereby should advance an exploration of the integrated relationship between cardiac energetics and function under physiological and pathological conditions.
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